RT Journal Article
T1 Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients.
A1 Piñana, José Luis
A1 Vázquez, Lourdes
A1 Martino, Rodrigo
A1 de la Cámara, Rafael
A1 Sureda, Anna
A1 Rodríguez-Veiga, Rebeca
A1 Garrido, Ana
A1 Sierra, Jorge
A1 Ribera, José-María
A1 Torrent, Anna
A1 Mateos, María Victoria
A1 de la Rubia, Javier
A1 Tormo, Mar
A1 Díez-Campelo, María
A1 García-Gutiérrez, Valentín
A1 Álvarez-Larrán, Alberto
A1 Sancho, Juan-Manuel
A1 MartínGarcía-Sancho, Alejandro
A1 Yañez, Lucrecia
A1 Pérez Simón, José Antonio
A1 Barba, Pere
A1 Abrisqueta, Pau
A1 Álvarez-Twose, Iván
A1 Bonanad, Santiago
A1 Lecumberri, Ramón
A1 Ruiz-Camps, Isabel
A1 Navarro, David
A1 Hernández-Rivas, José-Ángel
A1 Cedillo, Ángel
A1 García-Sanz, Ramón
A1 Bosch, Francesc
K1 COVID-19
K1 SARS-CoV-2 vaccine
K1 acute leukemia
K1 allogeneic stem cell transplantation
K1 lymphoma
K1 myelodisplastic syndrome
K1 myeloproliferative neoplasm
K1 onco-hematology
K1 stem cell transplantation
K1 vaccination consensus
AB In the midst of the COVID-19 pandemic, different vaccines in front of SARS-CoV-2 have been approved and administered in different vulnerable populations. As patients with cancer were excluded from pivotal trials of vaccination, little is known on their immunogenic response to these vaccines, particularly in patients with severely impaired immune system. In response to that uncertainty, the Spanish Society of Hematology and Hemotherapy launched an initiative aimed to provide recommendations for vaccination of the main hematological conditions. This document is based on the available information on COVID-19 outcomes, prior knowledge on vaccination in hematological patients, recent published data on serological response in oncohematological patients and expert opinions. New information about SARS-CoV-2 vaccination will be gathered in the near future, providing new scientific grounds to delineate the most adequate management of vaccination in patients with hematological diseases. The current limited data on SARS-CoV-2 vaccines in hematological patients represents a major limitation of this expert consensus opinion. In fact, the speed in which this field evolves may reduce their validity in the near future.
YR 2021
FD 2021-10-20
LK https://hdl.handle.net/10668/27272
UL https://hdl.handle.net/10668/27272
LA en
DS RISalud
RD Apr 6, 2025